Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity

Iván Henríquez, Gemma Sancho, Asunción Hervás, Benjamin Guix, Joan Pera, Cristina Gutierrez, Oscar Abuchaibe, Rafael Martínez-Monge, Alejandro Tormo, Alfredo Polo, Iván Henríquez, Gemma Sancho, Asunción Hervás, Benjamin Guix, Joan Pera, Cristina Gutierrez, Oscar Abuchaibe, Rafael Martínez-Monge, Alejandro Tormo, Alfredo Polo

Abstract

Purpose: To evaluate efficacy and toxicity after salvage brachytherapy (BT) in prostate local recurrence after radiation therapy.

Methods and materials: Between 1993 and 2007, we retrospectively analyzed 56 consecutively patients (pts) undergoing salvage brachytherapy. After local biopsy-proven recurrence, pts received 145 Gy LDR-BT (37 pts, 66%) or HDR-BT (19 pts, 34%) in different dose levels according to biological equivalent doses (BED(2 Gy)). By the time of salvage BT, only 15 pts (27%) received ADT. Univariate and multivariate analyses were performed to identify predictors of biochemical control and toxicities. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were graded using Common Terminology Criteria for Adverse Events (CTCv3.0).

Results: Median follow-up after salvage BT was 48 months. The 5-year FFbF was 77%. HDR and LDR late grade 3 GU toxicities were observed in 21% and 24%. Late grade 3 GI toxicities were observed in 2% (HDR) and 2.7% (LDR). On univariate analysis, pre-salvage prostate-specific antigen (PSA) > 10 ng/ml (p = 0.004), interval to relapse after initial treatment < 24 months (p = 0.004) and salvage HDR-BT doses BED(2 Gy) level < 227 Gy (p = 0.012) were significant in predicting biochemical failure. On Cox multivariate analysis, pre-salvage PSA, and time to relapse were significant in predicting biochemical failure. HDR-BT BED(2 Gy) (α/β 1.5 Gy) levels ≥ 227 (p = 0.013), and ADT (p = 0.049) were significant in predicting grade ≥ 2 urinary toxicity.

Conclusions: Prostate BT is an effective salvage modality in some selected prostate local recurrence patients after radiation therapy. Even, we provide some potential predictors of biochemical control and toxicity for prostate salvage BT, further investigation is recommended.

Figures

Figure 1
Figure 1
Kaplan-Meier freedom from biochemical failure post-salvage brachytherapy with 5-year estimates.

References

    1. Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer. 2007;110:1417–1428. doi: 10.1002/cncr.22941.
    1. Cox JM, Busby E. Salvage therapy for prostate cancer recurrence after radiation therapy. Curr Urol Rep. 2009;10:199–205. doi: 10.1007/s11934-009-0034-7.
    1. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54:880–883. doi: 10.1016/S0090-4295(99)00241-1.
    1. Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999;53:2–10. doi: 10.1016/S0090-4295(98)00492-0.
    1. Wong WW, Buskirk SJ, Schild SE, Prussak KA, Davis BJ. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol. 2006;176:2020–2024. doi: 10.1016/j.juro.2006.07.008.
    1. Allen GW, Howard AR, Jarrard DF, Ritter MA. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer. 2007;110:1405–1416. doi: 10.1002/cncr.22940.
    1. Nguyen PL, Chen MH, D’Amico AV, Tempany CM, Steele GS, Albert M. Magnetic resonance image-guided salvage brachytherapy after radiation in selected men who initially presented with favourable-risk prostate cancer: a prospective phase 2 study. Cancer. 2007;110:1485–1492. doi: 10.1002/cncr.22934.
    1. Lee HK, Adams MT, Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy. 2008;7:17–21. doi: 10.1016/j.brachy.2007.11.002.
    1. Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013;86:324–329. doi: 10.1016/j.ijrobp.2013.01.027.
    1. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int. 2009;104:600–604. doi: 10.1111/j.1464-410X.2009.08445.x.
    1. Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;77:1338–1344. doi: 10.1016/j.ijrobp.2009.06.061.
    1. Guix B, Lejarcegui JA, Tello JI, Zanón G, Henríquez I, Finestres F, Martinez A, Fernandez-Ibiza J, Quinzaños L, Palombo P, Encinas X, Guix I. Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study. Int J Radiat Oncol Biol Phys. 2010;78:804–810. doi: 10.1016/j.ijrobp.2009.08.009.
    1. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer [Review] 2006. (The Cochrane Library 2007). Available on line at .
    1. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041.
    1. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without androgen deprivation therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix. Int J Radiat Oncol Biol Phys. 2006;65:965–974. doi: 10.1016/j.ijrobp.2006.04.029.
    1. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer a/b ratio is low. Int J Radiat Oncol Biol Phys. 2001;51:213–214.
    1. Nag S, Martinez-Monge R, Copeland LJ, Vacarello L, Lewandowski GS. Perineal template intersticial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina. Gynecol Oncol. 1997;66:16–19. doi: 10.1006/gyno.1997.4722.
    1. Kovács G, Pötter R, Loch T, Hammer J, Kolkman-Deurloo IK, de la Rosette JJ, Bertermann H. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol. 2005;274:137–148.
    1. Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu J. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of task group 137. Med Phys. 2009;36:5310–5322. doi: 10.1118/1.3246613.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.1080/01621459.1958.10501452.
    1. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974. doi: 10.1001/jama.280.11.969.
    1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Sem Radiat Oncol. 2003;13:176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall’Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer. a multi-institutional collaboration. Eur Urol. 2011;60:205–210. doi: 10.1016/j.eururo.2011.03.011.
    1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597. doi: 10.1001/jama.281.17.1591.
    1. Tharp M, Hardacre M, Bennett R, Jones WT, Stuhldreher D, Vaught J. Prostate high-dose rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy. 2008;7:231–236. doi: 10.1016/j.brachy.2008.03.003.
    1. Levy DA, Li J, Jones JS. Disease burden predicts for favorable postsalvage cryoablation PSA. Urology. 2010;76:1157–1161. doi: 10.1016/j.urology.2010.01.053.
    1. Bianco FJ Jr, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:448–453. doi: 10.1016/j.ijrobp.2004.09.049.
    1. Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce De León J, Suárez JF, Boladeras A, Pont À, Ayala A, Sancho G, Martínez E, Alonso J, Ferrer M. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28:4687–4696. doi: 10.1200/JCO.2009.25.3245.
    1. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L. Quality of life and satisfaction withoutcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261. doi: 10.1056/NEJMoa074311.
    1. Cunha JA, Pouliot J, Weinberg V, Wang-Chesebro A, Roach M 3rd, Hsu IC. Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy. Brachytherapy. 2012;11:348–353. doi: 10.1016/j.brachy.2011.07.009.
    1. Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, Pisters LL. Salvage cryosurgery for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20:2664–2671. doi: 10.1200/JCO.2002.06.086.
    1. Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:559–563. doi: 10.1016/j.juro.2008.04.005.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir